FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2579747579> ?p ?o ?g. }

• W2579747579 abstract "We performed a randomized, double-blind, cross-over study to assess the neuroregenerative potential of intravenous granulocyte colony-stimulating factor (G-CSF) followed by infusion of mobilized peripheral blood mononuclear cells (mPBMCs) in children with cerebral palsy (CP). Children with non-severe CP were enrolled in this study. G-CSF was administered for 5 days, then mPBMCs were collected by apheresis and cryopreserved. One month later (M1), recipients were randomized to receive either mPBMCs or a placebo infusion, and these treatment groups were switched at 7 months (M7) and observed for another 6 months (M13). We assessed the efficacy of treatment by evaluating neurodevelopmental tests, as well as by brain magnetic resonance imaging-diffusion tensor imaging (MRI-DTI) and 18F-fluorodeoxyglucose (FDG) brain positron emission tomography-computed tomography (PET-CT) scanning to evaluate the anatomical and functional changes in the brain. Fifty-seven patients aged 4.3 ± 1.9 (range 2–10) years and weighing 16.6 ± 4.9 (range 11.6–56.0) kg were enrolled in this study. The administration of G-CSF as well as the collection and reinfusion of mPBMCs were safe and tolerable. The yield of mPBMCs was comparable to that reported in studies of pediatric donors without CP and patients with nonhematologic diseases. 42.6% of the patients responded to the treatment with higher neurodevelopmental scores than would normally be expected. In addition, larger changes in neurodevelopment test scores were observed in the 1 month after G-CSF administration (M0–M1) than during the 6 months after reinfusion with mPBMCs or placebo (M1–M7 or M7–M13). Patients who received G-CSF followed by mPBMC infusion at 7 months (T7 group) demonstrated significantly more neurodevelopmental improvement than patients who received G-CSF followed by mPBMC infusion at 1 month (T1 group). In contrast to the results of neurodevelopment tests, the results of MRI-DTI at the end of this study showed greater improvement in the T1 group. Although we observed metabolic changes to the cerebellum, thalamus and cerebral cortex in the 18F-FDG brain PET-CT scans, there were no significant differences in such changes between the mPBMC and placebo group or between the T1 and T7 group. Neurodevelopmental improvement was seen in response to intravenous G-CSF followed by mPBMC reinfusion, particularly to the G-CSF alone even without mPBMC reinfusion. Further studies using a larger number of mPBMCs for the infusion which could be collected by repeated cycles of apheresis or using repeated cycles of G-CSF alone, are needed to clarify the effect of mPBMC reinfusion or G-CSF alone (Trial registration: ClinicalTrials.gov, NCT02983708. Registered 5 December, 2016, retrospectively registered)." @default.
• W2579747579 created "2017-01-26" @default.
• W2579747579 creator A5023392413 @default.
• W2579747579 creator A5029073808 @default.
• W2579747579 creator A5031949024 @default.
• W2579747579 creator A5032979196 @default.
• W2579747579 creator A5047843177 @default.
• W2579747579 creator A5056977144 @default.
• W2579747579 creator A5071896585 @default.
• W2579747579 creator A5078380514 @default.
• W2579747579 creator A5079697987 @default.
• W2579747579 creator A5082438919 @default.
• W2579747579 creator A5085642896 @default.
• W2579747579 creator A5086851897 @default.
• W2579747579 creator A5087523620 @default.
• W2579747579 date "2017-01-21" @default.
• W2579747579 modified "2023-10-17" @default.
• W2579747579 title "Neuroregenerative potential of intravenous G-CSF and autologous peripheral blood stem cells in children with cerebral palsy: a randomized, double-blind, cross-over study" @default.
• W2579747579 cites W1522375197 @default.
• W2579747579 cites W1523051641 @default.
• W2579747579 cites W1559755301 @default.
• W2579747579 cites W1968847326 @default.
• W2579747579 cites W1979271564 @default.
• W2579747579 cites W1984230628 @default.
• W2579747579 cites W1990357530 @default.
• W2579747579 cites W2018350696 @default.
• W2579747579 cites W2024331107 @default.
• W2579747579 cites W2026485224 @default.
• W2579747579 cites W2034621766 @default.
• W2579747579 cites W2048347668 @default.
• W2579747579 cites W2065668736 @default.
• W2579747579 cites W2090437326 @default.
• W2579747579 cites W2095133117 @default.
• W2579747579 cites W2105688599 @default.
• W2579747579 cites W2109107907 @default.
• W2579747579 cites W2115668304 @default.
• W2579747579 cites W2119937060 @default.
• W2579747579 cites W2133101205 @default.
• W2579747579 cites W2141073813 @default.
• W2579747579 cites W2168867226 @default.
• W2579747579 cites W2231079609 @default.
• W2579747579 cites W2395438042 @default.
• W2579747579 doi "https://doi.org/10.1186/s12967-017-1120-0" @default.
• W2579747579 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5251252" @default.
• W2579747579 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28109298" @default.
• W2579747579 hasPublicationYear "2017" @default.
• W2579747579 type Work @default.
• W2579747579 sameAs 2579747579 @default.
• W2579747579 citedByCount "36" @default.
• W2579747579 countsByYear W25797475792017 @default.
• W2579747579 countsByYear W25797475792018 @default.
• W2579747579 countsByYear W25797475792019 @default.
• W2579747579 countsByYear W25797475792020 @default.
• W2579747579 countsByYear W25797475792021 @default.
• W2579747579 countsByYear W25797475792022 @default.
• W2579747579 countsByYear W25797475792023 @default.
• W2579747579 crossrefType "journal-article" @default.
• W2579747579 hasAuthorship W2579747579A5023392413 @default.
• W2579747579 hasAuthorship W2579747579A5029073808 @default.
• W2579747579 hasAuthorship W2579747579A5031949024 @default.
• W2579747579 hasAuthorship W2579747579A5032979196 @default.
• W2579747579 hasAuthorship W2579747579A5047843177 @default.
• W2579747579 hasAuthorship W2579747579A5056977144 @default.
• W2579747579 hasAuthorship W2579747579A5071896585 @default.
• W2579747579 hasAuthorship W2579747579A5078380514 @default.
• W2579747579 hasAuthorship W2579747579A5079697987 @default.
• W2579747579 hasAuthorship W2579747579A5082438919 @default.
• W2579747579 hasAuthorship W2579747579A5085642896 @default.
• W2579747579 hasAuthorship W2579747579A5086851897 @default.
• W2579747579 hasAuthorship W2579747579A5087523620 @default.
• W2579747579 hasBestOaLocation W25797475791 @default.
• W2579747579 hasConcept C126322002 @default.
• W2579747579 hasConcept C126838900 @default.
• W2579747579 hasConcept C141071460 @default.
• W2579747579 hasConcept C142724271 @default.
• W2579747579 hasConcept C143409427 @default.
• W2579747579 hasConcept C149550507 @default.
• W2579747579 hasConcept C168563851 @default.
• W2579747579 hasConcept C1862650 @default.
• W2579747579 hasConcept C204787440 @default.
• W2579747579 hasConcept C27081682 @default.
• W2579747579 hasConcept C2776694085 @default.
• W2579747579 hasConcept C2776738589 @default.
• W2579747579 hasConcept C2777767877 @default.
• W2579747579 hasConcept C2779421357 @default.
• W2579747579 hasConcept C2989005 @default.
• W2579747579 hasConcept C42219234 @default.
• W2579747579 hasConcept C71924100 @default.
• W2579747579 hasConcept C89560881 @default.
• W2579747579 hasConceptScore W2579747579C126322002 @default.
• W2579747579 hasConceptScore W2579747579C126838900 @default.
• W2579747579 hasConceptScore W2579747579C141071460 @default.
• W2579747579 hasConceptScore W2579747579C142724271 @default.
• W2579747579 hasConceptScore W2579747579C143409427 @default.
• W2579747579 hasConceptScore W2579747579C149550507 @default.
• W2579747579 hasConceptScore W2579747579C168563851 @default.
• W2579747579 hasConceptScore W2579747579C1862650 @default.
• W2579747579 hasConceptScore W2579747579C204787440 @default.
• W2579747579 hasConceptScore W2579747579C27081682 @default.
• W2579747579 hasConceptScore W2579747579C2776694085 @default.

• next